Pharma

Your Article Summary

See Latest Articles

Active Biotechs rights issue substantially oversubscribed
Active Biotech, 06/16/09

Active Biotech's rights issue of approximately 256 million SEK, with pre-emptive rights for the company's shareholders, has been completed. A count has shown that the issue is oversubscribed by 71 percent; 99.4 percent of the shares offered were subscribed for with the support of subscription rights.

Today in Biotechnology...keeping you current

Receive free subspecialty "5-minute updates" via email

ImmunoGen, Inc. Announces Clinical Data Presentations on Three TAP Compounds at Upcoming ASH Annual Meeting and Exposition
ImmunoGen, Inc., 11/25/09

ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09

Expanding The Biopharmaceutical Industry's Involvement In Fighting Neglected Diseases
Health Affairs, 11/19/09

 See all of Biotechnology